FOLH1 and prostate carcinoma: This was granted in December 2020, making [68Ga]Ga-PSMA-11 the first radiopharmaceutical for PET imaging of PSMA–positive lesions in men with prostate cancer approved in the US (Carlucci et al. 2021).